Éric Durot
A5040444445- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- CNS Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Historical Art and Culture Studies
- European Political History Analysis
- Immunodeficiency and Autoimmune Disorders
- Historical Influence and Diplomacy
- CAR-T cell therapy research
- Cardiac tumors and thrombi
- Acute Lymphoblastic Leukemia research
- Radiomics and Machine Learning in Medical Imaging
- Sarcoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Nail Diseases and Treatments
- Lung Cancer Treatments and Mutations
- Renal Diseases and Glomerulopathies
- Neuroendocrine Tumor Research Advances
- Immune Cell Function and Interaction
- Advanced Breast Cancer Therapies
- Otitis Media and Relapsing Polychondritis
- Historical Studies and Socio-cultural Analysis
- PI3K/AKT/mTOR signaling in cancer
Université de Reims Champagne-Ardenne
2016-2025
Centre Hospitalier Universitaire de Reims
2016-2025
Hôpital Robert-Debré
2012-2024
Institut Gustave Roussy
2019
Inserm
2019
Université Paris-Saclay
2019
La Ligue Contre le Cancer
2019
Acute Leukemia French Association
2019
Université de Lille
2018
Centre Hospitalier Universitaire de Lille
2018
Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies emerged since the development of International Prognostic Scoring System, and
Histological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 L265P mutation on transformation. We examined risk factors and outcomes associated WM, highlighting role mutation. Patients WM seen at Mayo Clinic, Rochester, USA University Hospital Reims, France, between 01/01/1996 December 31, 2017 were included; 50 (4.3%) 1147 patients transformed to a high-grade lymphoma, median...
Background Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for Hematopoietic Stem Cell Transplantation (HSCT) may benefit from a second line anticancer drug regimen but real-life outcomes are lacking. Objective To describe the efficacity of 3 regimens (Gemcitabine and Oxaliplatin GEMOX; Ifosfamide Etoposide IE; Cyclophosphamide, Etoposide, Procarbazine Prednisone CEPP) combined Rituximab (R-) in terms progression-free (PFS) overall survival (OS)....
<p>Supplementary figures and legends</p>
<div>Abstract<p>The ETS-domain transcription factors divide into subfamilies based on protein similarities, DNA-binding sequences, and interaction with cofactors. They are regulated by extracellular clues contribute to cellular processes, including proliferation transformation. <i>ETS</i> genes targeted through genomic rearrangements in oncogenesis. The <i>PU.1/SPI1</i> gene is inactivated point mutations human myeloid malignancies. We identified a...
ABSTRACT Introduction We retrospectively analysed bortezomib–dexamethasone–rituximab (BDR) combination in patients with Waldenström macroglobulinaemia (WM) a real world setting. Methods A total of 87 were included: 49 (56%) treated frontline, 22 (25%) second line and 16 (19%) third or further settings. log‐rank test was used to compare overall event‐free survival (OS EFS) whereas Gray's performed cumulative incidence deaths relapse (CID CIR) according the IPSS‐WM groups, MYD88/CXCR4...
Summary Histological transformation ( HT ) to diffuse large B‐cell lymphoma DLBCL is a rare and poorly reported complication of Waldenström macroglobulinaemia WM ). We performed retrospective study 77 patients with biopsy‐proven . The median time from diagnosis was 4·6 years 16 (21%) had never been treated for At , extranodal sites were observed in 91% rather high incidence central nervous system, cutaneous or testicular involvement. Fluorodeoxyglucose‐positron emission tomography half the...
Abstract Carmustine shortage has led to an increase use of alternative conditioning regimens prior autologous stem cell transplantation for the treatment lymphoma, including Bendamustine‐based (BeEAM). The aim this study was evaluate safety BeEAM regimen in a large cohort patients. A total 474 patients with median age 56 years were analyzed. majority had diffuse B‐cell lymphoma (43.5%). Bendamustine administered at dose 197 mg/m 2 /day (50‐250) on days‐7 and −6. observed grade 1‐4 toxicities...
Abstract Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive typically affecting young female patients. The first-line standard care remains debated. We performed large multicenter retrospective study in 25 centers France and Belgium to describe PMBL patient outcomes after treatment real-life settings. A total 313 patients were enrolled received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) (n = 180) or CHOP (cyclophosphamide,...
Abstract Primary mediastinal B-cell lymphoma (PMBL) is an uncommon entity of aggressive with unusually good prognosis, except for 10-15% chemotherapy-refractory cases. To identify earlier these higher risk patients, we performed molecular characterization a retrospective multicenter cohort patients treated firstline immunochemotherapy. The traits the gene-expression profiling data (n = 120) were as follows: median age 34 years (range, 18-67 years); female sex, 58.3%; elevated lactate...
Abstract The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for after autologous stem transplant (ASCT). Primary endpoint was time treatment failure (TTF), secondary endpoints included response rates,...
Abstract Ultra high‐risk chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS) usually display a poor prognosis. Platinum cytarabine‐based regimens have not been evaluated in large cohorts of patients with CLL or RS. This retrospective study was aimed to assess the efficacy these 75 relapsed/refractory (R/R) Forty‐seven had R/R (including 36 ultra CLL) 28 Median age 62 years (range, 18–79 years). number previous therapies 3 1–7), including fludarabine‐based (75%) alemtuzumab (32%),...
The ETS-domain transcription factors divide into subfamilies based on protein similarities, DNA-binding sequences, and interaction with cofactors. They are regulated by extracellular clues contribute to cellular processes, including proliferation transformation. ETS genes targeted through genomic rearrangements in oncogenesis. PU.1/SPI1 gene is inactivated point mutations human myeloid malignancies. We identified a recurrent somatic mutation (Q226E) Waldenström macroglobulinemia, B-cell...
Patients (pts) with asymptomatic low-burden follicular lymphoma (FL) are usually observed at diagnosis. Time to treatment (TLT) initiation can however be very heterogeneous and risk factors of progression poorly studied. Our study evaluated 201 pts grade 1-3a low-tumor burden FL diagnosed in four French centers between 2010 2020 managed by a watch wait strategy real-life settings. After median follow-up 4.8 years, the TLT was 4.2 years (95% confidence interval, 3.1-5.5). On multivariate...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Primary analysis of phase III randomized AATT study showed younger patients with peripheral T-cell lymphoma (PTCL)...